# IDEXX Q2 2022 Earnings Highlights (NASDAQ: IDXX)

•

.....

Revenue		Opera Pro		Diluted Earnings Per Share				
\$861M		\$17		\$1.56				
Reported growth: +4%		20.8% of R	evenue		u.,	(33%)		
Organic growth:	+6%	YoY change in basis points:		Reported grow	Reported growth:			
CAG Diagnostics Recurrin		Reported Comparable	(1060 bps (1050 bps	Comparable growth:		(30%)		
😡 CAG		🚺 Water 🕞 LPD						
Revenue	\$784M	Revenue	\$39M	Rever	nue	\$30M		
Reported growth:	+5%	Reported growth:	+5%	Reported grov	wth:	(11%)		
Organic growth:	+7%	Organic growth:	+9%	Organic growth:		(5%)		
Net CAG Revenue	Q2 Revenue	Reported Growth year over year	Organic Growth year over year	Q2 Premium Instrument Placements	WW	U.S.	Intl	
CAG Diagnostics Recurring	\$685M	+4%	+7%	Catalyst	1,959	699	1,260	
IDEXX VetLab <sup>®</sup> Consumables	\$266M	+4%	+8%	New and competitive	1,353	342	1,011	
Rapid Assay Products	\$87M	+4%	+6%	Second	494	347	147	
Reference Laboratory Dx and Consulting Services	\$304M	+4%	+6%	Premium Hematology	1,830	560	1,270	
CAG Diagnostics Services and Accessories	1 \$28M	+1%	+6%	SediVue <sup>®</sup> Dx	645	397	248	
CAG Diagnostics Capital – Instrumer	nts \$36M	+3%	+8%	TOTAL	4,434	1,656	2,778	
Veterinary Software, Services and Diagnostic Imaging Systems	\$62M	+27%	+14%					


•

. . . .

•••

IDEXX

#### **IDEXX** Premium Instruments Installed Base



For full financial data, non-GAAP reconciliations and cautionary language regarding forward-looking statements, please refer to IDEXX's 2022 second quarter earnings release issued on August 2, 2022 available at https://www.idexx.com/investors. Amounts presented may not recalculate due to rounding.

## IDEXX Q2 2022 Earnings Highlights (NASDAQ: IDXX)

#### 2022 Growth and Financial Performance Outlook Commentary

. .


- Updated revenue estimate reflects expectations for solid second half organic growth, including benefits from higher pricing, net of impacts from a stronger U.S. dollar and potential additional impacts from macroeconomic conditions.
  - Reported revenue growth of 3% 5.5% and organic growth of 5.5% 8% is driven by 6.5% 9% CAG Diagnostics recurring revenue organic growth
  - Operating margin outlook of 26.4% 26.9% includes 230 basis point impact related to discrete R&D investments in the second quarter
  - EPS estimate of \$7.77 \$8.05, a decrease of \$0.32 at midpoint compared to prior guidance. This reflects growth of (10%) (6%) as reported and (4%) (1)% on a comparable basis, including \$0.72 per share or 9% EPS growth impact related to discrete R&D investments and adjustments to reflect FX changes and higher interest rates.

Growth	2022				
	Revenue	\$3,305	-	\$3,385	
	Reported growth	3%	-	5.5%	
	Organic growth	5.5%	-	8%	
	CAG Diagnostics Recurring Revenue Growth				
	Reported growth	4%	-	6%	
	Organic growth	6.5%	-	9%	
	Operating Margin	26.4%	-	26.9%	
	Reported margin expansion	(260 bps)	-	(210 bps)	
	Impact of foreign exchange	~ 20 bps			
	Comparable margin expansion	(280 bps)	-	(230 bps)	
	Impact of discrete in-license of technology	(230 bps)			
	EPS	\$7.77	-	\$8.05	
-669	Reported growth	(10%)	-	(6%)	
	Comparable growth	(4%)	-	(1%)	
	Other Key Metrics				
	Net interest expense	\$38	-	\$39	
	Share-based compensation tax benefit	~ \$10			
	Effective tax rate	21.5%	-	22%	
	Reduction of average shares outstanding	~ 2.0%			
	Operating Cash Flow	90% - 95% of net income			
	Free Cash Flow	65% - 70% of net income			
	Capital Expenditures	~ \$180			

Amounts in millions except per share data and percentages; parentheses denote year-over-year decline or contraction

For full financial data, non-GAAP reconciliations and cautionary language regarding forward-looking statements, please refer to IDEXX's 2022 second quarter earnings release issued on August 2, 2022 available at https://www.idexx.com/investors. Amounts presented may not recalculate due to rounding.





*Total visits* include clinical and non-clinical visits. In 2021, there were an estimated 340 million U.S. total visits. Approximately 70% of estimated U.S. companion animal diagnostic sector revenue is from non-wellness visits.

Clinical visits are those where the reason for visit involves an interaction between a clinician and a pet.

Non-wellness visits include those for which the reason for visit is sickness, procedure or monitoring.

Wellness visits include those visits for which the reason for visit is an annual exam, vaccination, or routine check-up.


\* Note that we estimate net new practice formation adds ~1% of incremental market growth per year beyond per practice growth.

Source: IDEXX Practice Intelligence data; sample of ~9,100 practices representing six different practice information management systems, weighted based on practice size and region to reflect market composition.

<sup>\*\*</sup> Growth rate estimate with margin of error of +/ - 0.4% at a 95% confidence level.



### Contributors to U.S. Companion Animal Diagnostic Revenue Growth per Practice\*\*



\*\* Rounded to nearest 50 bps.

\*\*\* Diagnostic revenue per clinical visit includes volume/ intensity of Dx activity and net price realization.

Source: IDEXX Practice Intelligence data; sample of ~9,100 practices representing six different practice information management systems, weighted based on practice size and region to reflect market composition.

